Compare Citra Nusantara Gemilang Tbk. (CGAS) vs Prodia Diagnostic Line Tbk (PRDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citra Nusantara Gemilang Tbk. vs Prodia Diagnostic Line Tbk — how do they compare? Citra Nusantara Gemilang Tbk. trades at Rp149 (market cap 263.95B), while Prodia Diagnostic Line Tbk trades at Rp270 (market cap 470.58B). The key difference: Prodia Diagnostic Line Tbk is the larger of the two by market cap. Which is the better fit depends on your goals.
| CGAS | PRDL | |
|---|---|---|
Market Cap | 263.95B | 470.58B |
Indicative Equilibrium Price | — | 272 |
Indicative Equilibrium Volume | — | 415 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citra Nusantara Gemilang Tbk.
PT Citra Nusantara Gemilang Tbk (the “Company”), was established based on Notarial Deed No. 22, dated December 21, 2005 of Edi Priyono, S.H.. The Company's parent entity is PT Petro Asia Energy
Read more on CGAS →About Prodia Diagnostic Line Tbk
PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →
